Jeffrey Hafkin

Jeffrey Hafkin

Company: Otsuka

Job title: Senior Director


An Overview of the “Visionary” Study: A Phase 3 Trial of Sibeprenlimab for IgA Nephropathy 4:30 pm

Explore the current approach to IgAN treatment Understand the need for new therapies for IgAN Examine the role of the APRIL pathway in the pathogenesis of IgANRead more

day: Day One

© Copyright 2022 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.